Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Expected to Reach $206,675 Thousand,Globally, by 2023 According to a new report published by Allied Market Research, titled, " Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 20172023," the global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023. Aneurysmal subarachnoid hemorrhage is a kind of stroke, which is caused by bleeding in the subarachnoid space of the brain. The major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such as smoking and alcohol consumption increase the risk for aSAH, as well as rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension, and stroke further boost the market growth. However, the associated side effects of the drugs are expected to impede the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.
Get sample copy of this report at: https://www.alliedmarketresearch.com/request-sample/4602